A recent study shows rapid relapse of coronavirus disease 2019 (COVID-19) symptoms following the administration of nirmatrelvir/ritonavir in adults, reports News Medical.
Nirmatrelvir inhibits the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and blocks viral replication. The antiviral drug markedly lowers disease severity in at-risk individuals.
The study and findings
The present study observed the relapse of COVID-19 symptoms and viral load after an early…